for the Period Ended 31 December 2023
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
As at
Notes | 2023 | 2022 | |
---|---|---|---|
|
£ |
£ |
|
Current assets | |||
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Creditors: amounts falling due within one year: | 3 |
(
|
(
|
Net current assets (liabilities): |
( |
( |
|
Total assets less current liabilities: |
( |
( |
|
Total net assets (liabilities): |
( |
( |
|
Members' funds | |||
Profit and loss account: |
( |
( |
|
Total members' funds: |
( |
( |
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2023
Basis of measurement and preparation
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Other creditors |
|
|
Total |
|
|
The EAASM has had another successful year, and has fulfilled its CIC obligations admirably, and the Summer newsletter highlights this and can be found at www.eaasm.eu. The EAASM continues its major medication error and traceability patient safety project with the aim to significantly reduce medication errors by enhancing traceability processes. A Scientific Committee was further consulted on the generation of the comprehensive survey established along with a growing number of academic and hospital/healthcare organisations (now numbering 21). The project has its own website and the completed pan EU survey across 13 countries including the private hospital association has been kept extant. The results have contributed to a Call to Action White Paper within the EU institutions - mainly DG Sante. A round table was held in March 2022 to publicise the results of the survey and to commence the Call to Action. A comprehensive website has now been established (www.ECA-MET.EU). The EAASM is advocating for the inclusion of measures to reduce medication errors within various EU instruments such as the new EU pharmaceutical strategy and its attached legislation. More recently, a new White Paper was published highlighting the dangers of staff shortage and burn out by nurses in the area of oncology and how this will increase the risk of medication errors. The EAASM continues to be actively involved with the EU Parlimant and attends relevant meetings and contributes to healthcare debates in the Parliament bringing together MEPs, Commission and the Council. The EAASM continues to support the objectives and recommendations for the Pharmaceutical Strategy for Europe with the EU healthcare Coalition to which it is a partner. The EAASM recalls that the internet is the largest unregulated pharmaceutical marketplace in the world, with 62% of medicines purchased online being falsified or substandard with 95.6% of online pharmacies researched operating illegally. The EAASM calls on the European Commission and the Member States to build on the introduction of the Common Logo for online pharmacies (Implementing Regulation No 699/2014) and to extend it to a Europe-wide protocol for licensing online pharmacies which could potentially align with the pre-qualifications of the .pharmacy domain suffix, which is well governed by the National Association of Boards of Pharmacy. Whilst the DOTPharmacy NABP top level domain name initiative largely resides within the ASOP EU Company, the EAASM continues to support this important activity. Recently, a survey has been sent to those responsible for the administration of the Falsified Medicines Directive - the Common Logo. It will use the results to advocate for greater education of the public as to falsified medicines and also what the Common Logo stands for. The EAASM during 2023 continues its strong advocacy work to effect change of legislation so that nanomedicines and nonosimilars should be assesses by an EMA centralised procedure. In this regard, the EAASM along with the nanomedicines coalition achieved two important amendments in the EU Parliament Own Initiative Report. A number of meetings have been held with DG Sante to raise awareness about this subject which has patient safety implications. Following on from the EU Parliment Round Table, the nanomedicines coalition website still provides a useful presence for this patient safety initiative. The personal email from DG Sante confirmed that the GPL had in fact been charged to cover our patient safety requirements. In 2023, a survey was carried out in a number of EU Member States to understand the existing knowledge around nanomedicines and nanosimilars. This survey has been written and will be submitted to an appropriate scientific journal.
The above mentioned topics and activites have been communicated to its members and the EAASM board (a board meeting was held on 21 June 2024) to review and agree the above activities and concomitant objectives. communication regarding funding takes place with its members every year.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
12 August 2024
And signed on behalf of the board by:
Name: M P Isles
Status: Director